Belite Bio, Inc (NASDAQ:BLTE) Receives $44.83 Average Price Target from Brokerages

Belite Bio, Inc (NASDAQ:BLTE – Get Free Report) has earned a consensus recommendation of “Buy” from the seven analysts that are covering the company, Marketbeat Ratings reports. Seven analysts have rated the stock with a buy rating. The average 1 year price objective among brokerages that have issued a report on the stock in the […]

Leave a Reply

Your email address will not be published.

Previous post Gaskin: This is not the time to be a nation of bystanders
Next post Brokerages Set National Health Investors, Inc. (NYSE:NHI) Target Price at $60.50